Ciprofibrate diminishes non-HDL-c and improves HDL-c in patients with frederickson type IV dyslipidemia phenotype
Year: 2006
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: "Hypertriacylglyceridemia and low HDLc combination is one of the most common lipidic abnormalities. Thus, the aim of this study was to determine the effects of Ciprofibrate on patients with Frederickson¿s Type IV dyslipidemia phenotype. 75 patients with type IV dyslipidemia were assigned at random to one of two therapeutic options: Group A, AHA diet and physical activity and B, AHA diet, physical activity and Ciprofibrate 100 mg daily for 12 weeks. All patients underwent lipidic profile quantification before and after therapeutic intervention. Ciprofibrate treatment group exhibited significantly reduction in total cholesterol (-14,2% vs. -4,8%; p<0,02), triglycerides (-38% vs. -21,6%; p<0,007), VLDLc (-38% vs. -21,6%; p<0,007) Non-HDLc (-20,5% vs. -7,1%; p<0,007) and total cholesterol to HDLc ratio (-25,6 % vs. -9,4%; p<0,01) when comparing with diet/physical activity group . HDLc showed an important increase in Ciprofibrate group when contrast with diet/physical activity group (+25% vs. +9,6%, p<0,02). Ciprofibrate treatment effectively reduced triglycerides rich particles and Non-HDLc and significantly increased HDLc, proving it¿s usefulness in low HDLc syndrome and type IV Frederickson's hyperlipidemia."
Authors: Valmore Bermúdez, Aída Souki, Clímaco Cano-Ponce, Fernando Bermúdez-Arias, Edgardo Mengual-Moreno, Elliuz Leal-González, Miguel Lemus-Antepaz, Mayela Cabrera de Bravo, Anilsa Amell de Díaz, Nilka Leal de Pirela, Raquel Cano-Peñaloza, Guillermo Puche-Medina, Irene Ramírez, Freddy Contreras, Manuel Velasco
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W12825856